Show simple item record

dc.contributor.authorBrenman, NF
dc.contributor.authorMilne, Richard
dc.date.accessioned2022-04-12T18:00:14Z
dc.date.available2022-04-12T18:00:14Z
dc.date.issued2022-05
dc.identifier.citationScience, Technology, & Human Values, volume 47, issue 3, page 597-622
dc.identifier.issn0162-2439
dc.identifier.other10.1177_01622439211007196
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336037
dc.description.abstract<jats:p> “Readiness cohorts” are an innovation in clinical trial design to tackle the scarcity of time and people in drug studies. This has emerged in response to the challenges of recruiting the “right” research participants at the “right time” in the context of precision medicine. In this paper, we consider how the achievement of “readiness” aligns temporalities, biologies, and market processes of pharmaceutical innovation: how the promise of “willing bodies” in research emerges in relation to intertwined economic and biological time imperatives. Drawing on long-term engagement with the field of Alzheimer’s disease prevention and interviews with researchers from academia and the pharmaceutical industry, we describe the discursive construction and practical arrangement of readiness. This paper contributes to understandings of temporal specificity, or “timing,” within prevention research and casts critical light on the way this specificity—the threshold for “trial readiness”—relates to an opaque and highly speculative drug development pipeline. Extending the study of biomedical potential, as that which holds promise but may not yet exist, we consider how absences operate in adaptive trials. By highlighting these absences (“ready for what?”), we outline an opportunity for socio-ethical research to intervene in the speculative gaps of drug development. </jats:p>
dc.languageen
dc.publisherSAGE Publications
dc.subjectArticles
dc.subjectclinical trials
dc.subjectAlzheimer’s disease
dc.subjectethics
dc.subjectspeculation
dc.subjecttime
dc.subjectreadiness
dc.title“Ready for What?”: Timing and Speculation in Alzheimer’s Disease Drug Development
dc.typeArticle
dc.date.updated2022-04-12T18:00:14Z
prism.publicationNameScience Technology and Human Values
dc.identifier.doi10.17863/CAM.83466
rioxxterms.versionofrecord10.1177/01622439211007196
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
rioxxterms.licenseref.startdate2021-04-22
datacite.contributor.supervisorguest-editor: Taebi, Behnam
datacite.contributor.supervisorguest-editor: van de Poel, Ibo
dc.contributor.orcidBrenman, NF [0000-0002-6567-2129]
dc.contributor.orcidMilne, Richard [0000-0002-8770-2384]
dc.identifier.eissn1552-8251
pubs.funder-project-idInnovative Medicines Initiative (115736)
cam.issuedOnline2021-04-22
rioxxterms.freetoread.startdate2021-04-22
rioxxterms.freetoread.startdate2021-04-22


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record